| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14728222.2013.842978 |
| P698 | PubMed publication ID | 24206363 |
| P50 | author | Eng-King Tan | Q67189690 |
| P2093 | author name string | Dario C Angeles | |
| Sharon L Chan | |||
| P2860 | cites work | A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations | Q57623830 |
| Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain | Q57983267 | ||
| Lrrk2 pathogenic substitutions in Parkinson's disease | Q57983291 | ||
| LRRK2G2019S as a Cause of Parkinson's Disease in North African Arabs | Q58489573 | ||
| A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease | Q58870346 | ||
| A protein factor essential for microtubule assembly | Q22010837 | ||
| Parkinson's disease: clinical features and diagnosis | Q22242021 | ||
| Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity | Q22254785 | ||
| Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression | Q24293587 | ||
| LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress | Q24294466 | ||
| The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity | Q24297634 | ||
| LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis | Q24299176 | ||
| Progressive degeneration of human neural stem cells caused by pathogenic LRRK2 | Q24301070 | ||
| The R1441C mutation of LRRK2 disrupts GTP hydrolysis | Q24303406 | ||
| Kinase activity of mutant LRRK2 mediates neuronal toxicity | Q24303603 | ||
| LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth | Q24304347 | ||
| LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models | Q24304959 | ||
| Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant | Q24306788 | ||
| RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk | Q24315688 | ||
| LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction | Q24316894 | ||
| Localization of LRRK2 to membranous and vesicular structures in mammalian brain | Q24318643 | ||
| Interplay of LRRK2 with chaperone-mediated autophagy | Q24322747 | ||
| Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death | Q24323228 | ||
| LRRK2 regulates synaptic vesicle endocytosis | Q24336523 | ||
| Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity | Q24338647 | ||
| 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization | Q24339094 | ||
| Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of α-synuclein and LRRK2 in the brain | Q24599233 | ||
| Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies | Q24606055 | ||
| Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons | Q24628425 | ||
| Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells | Q24651391 | ||
| Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? | Q27026262 | ||
| Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis | Q27315276 | ||
| Alpha-synuclein in Lewy bodies | Q27860680 | ||
| Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
| Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments | Q28141728 | ||
| Biomarkers and surrogate endpoints: preferred definitions and conceptual framework | Q28203935 | ||
| Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease | Q28292932 | ||
| Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice | Q28507051 | ||
| Leucine-rich repeat kinase 2 associates with lipid rafts | Q28591286 | ||
| The pathophysiology of mitochondrial cell death | Q29547893 | ||
| Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease | Q29614900 | ||
| LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity | Q29615144 | ||
| Rab conversion as a mechanism of progression from early to late endosomes | Q29616151 | ||
| Kinase activity is required for the toxic effects of mutant LRRK2/dardarin | Q29620478 | ||
| Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers | Q30525550 | ||
| Biomarkers in Parkinson's disease (recent update). | Q30650927 | ||
| The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation | Q33525587 | ||
| Disruption of the MAP1B-related protein FUTSCH leads to changes in the neuronal cytoskeleton, axonal transport defects, and progressive neurodegeneration in Drosophila | Q33768542 | ||
| Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation | Q33808789 | ||
| Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein | Q33865491 | ||
| Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models | Q33964804 | ||
| Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease | Q34112588 | ||
| Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease | Q34267681 | ||
| Roc, a Ras/GTPase domain in complex proteins | Q34280792 | ||
| Microtubule destabilization is shared by genetic and idiopathic Parkinson's disease patient fibroblasts | Q34292484 | ||
| Αlpha-synuclein levels in blood plasma from LRRK2 mutation carriers | Q34540556 | ||
| Distinct autophagosomal-lysosomal fusion mechanism revealed by thapsigargin-induced autophagy arrest | Q34630595 | ||
| Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study | Q35525896 | ||
| LRRK2 Parkinson disease mutations enhance its microtubule association. | Q35688632 | ||
| Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning | Q35771011 | ||
| Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. | Q35780973 | ||
| Phosphorylation of α-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans | Q35802054 | ||
| Quantitative functions of Argonaute proteins in mammalian development. | Q35882150 | ||
| Brain Penetrant LRRK2 Inhibitor | Q36305876 | ||
| Vps9 domain-containing proteins: activators of Rab5 GTPases from yeast to neurons | Q36332014 | ||
| Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage | Q36584712 | ||
| Pathogenic mutations in Parkinson disease | Q36770206 | ||
| Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization | Q36780383 | ||
| Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila | Q36891456 | ||
| The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules | Q36982616 | ||
| Rab5 modulates aggregation and toxicity of mutant huntingtin through macroautophagy in cell and fly models of Huntington disease | Q37083085 | ||
| Molecular biology changes associated with LRRK2 mutations in Parkinson's disease | Q37109492 | ||
| Update on the functional biology of Lrrk2. | Q37395783 | ||
| LRRK2 in Parkinson's disease: genetic and clinical studies from patients | Q37608624 | ||
| LRRK2 and Parkinson disease | Q37748314 | ||
| α-Synuclein: membrane interactions and toxicity in Parkinson's disease | Q37760521 | ||
| Development of Parkinson’s disease biomarkers | Q37810992 | ||
| Mouse models for LRRK2 Parkinson's disease | Q37968047 | ||
| Genetic variants in sporadic Parkinson's disease: East vs West | Q37968081 | ||
| The neuropathology of genetic Parkinson's disease | Q37997386 | ||
| A link between LRRK2, autophagy and NAADP-mediated endolysosomal calcium signalling | Q38044445 | ||
| Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology. | Q38044449 | ||
| Cerebrospinal fluid biomarkers in Parkinson disease | Q38082586 | ||
| Microtubule-associated protein 1B (MAP1B) is required for dendritic spine development and synaptic maturation | Q39242448 | ||
| Activation of FoxO by LRRK2 induces expression of proapoptotic proteins and alters survival of postmitotic dopaminergic neuron in Drosophila. | Q39681242 | ||
| Interaction of elongation factor 1-alpha with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro | Q39832357 | ||
| Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration? | Q39834913 | ||
| Autophagy and microtubules - new story, old players. | Q42437740 | ||
| The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway | Q42509261 | ||
| Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration | Q42826736 | ||
| Role of Drosophila Rab5 during endosomal trafficking at the synapse and evoked neurotransmitter release | Q42917089 | ||
| Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons | Q43120316 | ||
| LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity | Q44483853 | ||
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. | Q46024777 | ||
| Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation | Q46587417 | ||
| Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease | Q48206843 | ||
| Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism | Q48248911 | ||
| Frequency of LRRK2 mutations in early- and late-onset Parkinson disease | Q48392751 | ||
| LRRK2 I2020T mutation is associated with tau pathology | Q48554539 | ||
| Early-onset familial parkinsonism due to POLG mutations | Q50278596 | ||
| Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. | Q53612457 | ||
| LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. | Q55041570 | ||
| LRRK2 protein is a component of lewy bodies | Q57341629 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 1471-1482 | |
| P577 | publication date | 2013-11-09 | |
| P1433 | published in | Expert Opinion on Therapeutic Targets | Q5421214 |
| P1476 | title | Targeting leucine-rich repeat kinase 2 in Parkinson's disease | |
| P478 | volume | 17 |
| Q35990800 | Antioxidants inhibit neuronal toxicity in Parkinson's disease-linked LRRK2 |
| Q38619109 | Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes |
| Q36237695 | Differential effect of caffeine intake in subjects with genetic susceptibility to Parkinson's Disease |
| Q47161571 | Genetic Analysis of LRRK2 R1628P in Parkinson's Disease in Asian Populations. |
| Q39263032 | Targeting LRRK2 in Parkinson's disease: an update on recent developments |
| Q26738459 | The biomarkers of immune dysregulation and inflammation response in Parkinson disease |
Search more.